Genmab initiates phase III cancer treatment study  

2006.07.17
Danish biotech company Genmab has initiated a phase III study of HuMax-CD20 for the treatment of a form of cancer called non-Hodgkin’s lymphoma

Danish biotech company Genmab has initiated a phase III study of HuMax-CD20 for the treatment of a form of cancer called non-Hodgkin’s lymphoma (NHL) in patients who do not respond to the current product on the market, rituximab. Genmab's share price rose immediately on the news.

The study will include approximately 162 NHL patients and disease status will be assessed every 3 months until month 24. The aim is to determine the efficacy and safety of two dose regimens of HuMax-CD20. This will be assessed by an independent review committee according to standardized criteria for NHL. If all goes to plan and the product gains the necessary approvals for use in NHL, it could be on the market by 2008.

Genmab A/S creates and develops human antibodies for the treatment of life-threatening and debilitating diseases. The company has a portfolio of products in development to treat cancer, infectious disease, rheumatoid arthritis and other inflammatory conditions. Genmab currently has multiple partnerships to gain access to disease targets and develop novel human antibodies including agreements with Roche, Amgen and Serono. Genmab has operations in Copenhagen, Denmark, Utrecht, the Netherlands, and Princeton, New Jersey in the US.

Link > Genmab 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×